I-125 monoclonal antibody A33

Drug Profile

I-125 monoclonal antibody A33

Alternative Names: A33-radionuclides; CDP 833; hA33 90Y

Latest Information Update: 25 Jan 1999

Price : $50

At a glance

  • Originator Celltech Group
  • Class Antineoplastics; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Colorectal cancer

Most Recent Events

  • 25 Jan 1999 Discontinued-I for Colorectal cancer in USA (IV)
  • 01 Oct 1997 A study has been added to the therapeutic trials and adverse events sections
  • 20 Aug 1997 CDP 833 is now called I-125 monoclonal antibody A33
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top